PT-141 (Bremelanotide) — central melanocortin agonist for sexual function
In short
Melanocortin agonist with MC4R affinity studied in neuroendocrine models for central regulation of sexual function.
Overview
PT-141 (Bremelanotide) is an -approved synthetic peptide that acts as a melanocortin receptor agonist, specifically targeting MC3R and MC4R receptors in the central nervous system. Unlike traditional ED medications that work through vascular mechanisms, PT-141 directly influences sexual arousal pathways in the brain, making it effective for both male and female sexual dysfunction.
Activates melanocortin receptors (MC3R/MC4R) in the central nervous system, triggering sexual arousal pathways independent of vascular mechanisms
Molecular information
First-order decay curve at 2.7h half-life from literature. Educational only.
Research indications
Grouped by area. Each entry reflects a separate published hypothesis or clinical signal - not medical advice.
RECONNECT (n=856) showed +0.54 FSFI vs +0.27 placebo over 24 weeks — basis for approval as Vyleesi.
Nausea
common·Vyleesi label
Transient BP rise (5-10 mmHg)
common
Flushing
common
Headache
common
Injection-site reaction
common
Focal hyperpigmentation (rare, >8/month)
rare
5 peer-reviewed sources
References
Links to peer-reviewed publications on PubMed, cited in the peptide's scientific profile.
RECONNECT
Phase 3 RCT | 1.75 mg s.c. | 24 weeks | +0.54 FSFI vs +0.27 placebo (n=856)
Obstet Gynecol · 2019
View the studyInformation about PT-141 is based on published scientific research and is intended for research purposes only. Not medical advice.
Products are for in vitro laboratory research only. Not approved for human consumption.
Other peptides
5-Amino-1MQ
5-Amino-1MQ is a small-molecule selective inhibitor of NNMT (nicotinamide N-methyltransferase), identified by Anthony Sauve (Cornell) in 2018. NNMT is a "metabolic sink" for methyl donors and NAD+ — suppressing it in adipocytes raises energy expenditure without reducing calorie intake.
ReadAdipotide
Adipotide is a target peptide developed by Wadih Arap and Renata Pasqualini (MD Anderson) for selective elimination of white adipose tissue. It binds prohibitin on adipocyte vasculature and induces apoptosis of the blood vessels supplying fat tissue — leading to nonsurgical fat reduction.
ReadAOD-9604
AOD-9604 is a modified C-terminal 16-amino-acid fragment of human growth hormone (177-191), supplemented with a tyrosine residue. Retains the lipolytic effect of the full molecule but without diabetogenic or GH-stimulating activity. Developed by Metabolic Pharmaceuticals (Australia) in the 1990s.
ReadARA-290
ARA-290 (Cibinetide) is an 11-amino-acid fragment of erythropoietin (EPO) developed by Anthony Cerami as a cytoprotective molecule without erythropoietic activity. It retains the tissue-protective effects of EPO without raising hematocrit — explaining its potential in diabetic neuropathy and cardiac applications.
ReadArgireline
Argireline is a synthetic acetylated hexapeptide (Ac-Glu-Glu-Met-Gln-Arg-Arg-NH2) derived from SNAP-25 — the SNARE complex subunit mediating acetylcholine release at neuromuscular junctions. Topical application reduces muscle activity in expression areas — which is why Argireline is marketed as a "topical Botox alternative".
ReadBPC-157
BPC-157 is a 15-amino-acid fragment isolated from a protective protein in human gastric juice — hence the name Body Protection Compound. Over thirty years of research by Predrag Sikiric's group at the University of Zagreb (100+ peer-reviewed papers) establish its angiogenic action through the VEGFR2 receptor and its stimulation of fibroblasts. If you work with in vitro models of tendon, muscle or gut tissue, BPC-157 is among the most extensively documented regenerative peptides.
ReadEducation
No comments yet. Be the first.
Comments are reviewed before publishing.
